IMV Inc.

DPX-RSV

DPX-RSV, a Vaccine to Address an Unmet Medical Need

Another Approach to Prophylactic Vaccines

DPX-RSV or DPX-RSV(A) is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The DPX platform is formulated with the SHe peptide of group A RSV. The small hydrophobic glycoprotein (SH) of RSV is a type II transmembrane protein that forms pentameric transmembrane pores in infected cells. It functions as a viral ion channel and might impact viral fusion.1

RSV is the leading cause of early childhood bronchiolitis and pneumonia worldwide and results in significant hospitalizations in infants, the elderly, and immunocompromised individuals. To date, no prophylactic RSV vaccine has been approved for clinical use and there is an increasing recognition of the unmet medical need for an effective RSV vaccine for older persons.2

1 Gan SW, J Biol Chem, 2012

2 Falsey AR et al. Med Mal Infect. 2005

A Vaccine Specifically Designed to Address RSV

DPX-RSV At-a-Glance

Safety and Long-Term Efficacy in Aged Adults

Our Phase 1 clinical trial in 50–64-year-old healthy adults demonstrated DPX-RSV to be safe and well tolerated and induced robust antigen-specific serum IgG responses that were sustained for more than a year. We saw a 100X increase of target antibody titers in all the subjects who receive a 0.025mg dose of the vaccine.1

Generates Robust Cellular and Humoral Immune Response

Our phase 1 clinical study demonstrated: a favorable isotype profile of SHe-specific antibodies, including IgG1, IgG3 and IgA, and cellular immune response that includes CD4+ T cell responses.2

Validation of DPX as a Useful Platform For Vaccination

Phase 1 clinical data also validate the application of the DPX technology in the infectious disease setting.

1 Schepens B et al. Immunotherapy, 2015

1 Langley JM et al, J. Infect. Dis 2018

2 Torrey HL et al, Human Vacc & Imm, 2020

Market Landscape for RSV

Respiratory Syncytial Virus

The World Health Organization (WHO) has designated RSV a high priority vaccine target.

64M

Infections caused by RSV

160K

Deaths each year